RU2016107378A3 - - Google Patents

Download PDF

Info

Publication number
RU2016107378A3
RU2016107378A3 RU2016107378A RU2016107378A RU2016107378A3 RU 2016107378 A3 RU2016107378 A3 RU 2016107378A3 RU 2016107378 A RU2016107378 A RU 2016107378A RU 2016107378 A RU2016107378 A RU 2016107378A RU 2016107378 A3 RU2016107378 A3 RU 2016107378A3
Authority
RU
Russia
Application number
RU2016107378A
Other languages
Russian (ru)
Other versions
RU2016107378A (ru
RU2734760C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016107378A publication Critical patent/RU2016107378A/ru
Publication of RU2016107378A3 publication Critical patent/RU2016107378A3/ru
Application granted granted Critical
Publication of RU2734760C2 publication Critical patent/RU2734760C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016107378A 2013-08-02 2014-08-01 Противоинфекционные соединения RU2734760C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361861750P 2013-08-02 2013-08-02
US61/861,750 2013-08-02
PCT/EP2014/066614 WO2015014993A2 (en) 2013-08-02 2014-08-01 Anti-infective compounds

Publications (3)

Publication Number Publication Date
RU2016107378A RU2016107378A (ru) 2017-09-07
RU2016107378A3 true RU2016107378A3 (enExample) 2018-03-29
RU2734760C2 RU2734760C2 (ru) 2020-10-23

Family

ID=51260879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016107378A RU2734760C2 (ru) 2013-08-02 2014-08-01 Противоинфекционные соединения

Country Status (12)

Country Link
US (1) US20160185774A1 (enExample)
EP (1) EP3027615B1 (enExample)
JP (3) JP2016525562A (enExample)
KR (1) KR102292293B1 (enExample)
CN (2) CN105745208A (enExample)
DK (1) DK3027615T3 (enExample)
ES (1) ES2883565T3 (enExample)
HU (1) HUE056198T2 (enExample)
PH (1) PH12016500207A1 (enExample)
RU (1) RU2734760C2 (enExample)
SG (1) SG11201600686QA (enExample)
WO (1) WO2015014993A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3316969T2 (ro) * 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
PE20181352A1 (es) * 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
EP3472152A1 (en) * 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111246848A (zh) 2017-10-05 2020-06-05 快尔生物技术公司 与抗结核药物组合的环稠和的噻唑并2-吡啶酮
CN108101828B (zh) * 2018-01-15 2021-05-04 西华师范大学 3-吲哚基甲酰胺类化合物及其制备方法
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
TWI861208B (zh) * 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
CN114423758B (zh) * 2019-09-13 2025-05-27 爱尔兰詹森科学公司 抗细菌化合物
KR20220071199A (ko) * 2019-09-30 2022-05-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4-퀴놀리논 항균 화합물
CA3151712A1 (en) * 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
IL328855A (en) 2019-12-20 2026-08-01 Qurient Co Ltd Q203 Pharmaceutical Oral Dosage Form
KR102381397B1 (ko) * 2020-07-10 2022-03-30 경희대학교 산학협력단 신규 나프토퀴논 유도체 화합물 및 이를 포함하는 항균용 조성물
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
JP2025530847A (ja) * 2022-09-16 2025-09-17 北京華益健康薬物研究中心 Mettl3阻害剤化合物、その医薬組成物及び用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
JP2026525955A (ja) 2023-07-18 2026-08-04 ヤンセン ファーマシューティカ エヌ.ベー. ベダキリン、プレトマニド又はデラマニド、及びシトクロムbc1阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用
CN117946118A (zh) * 2024-01-15 2024-04-30 珃诺生物医药科技(杭州)有限公司 一种靶向降解erk5蛋白的化合物及其制备方法
CN119118959A (zh) * 2024-09-06 2024-12-13 镇江市高等专科学校 4-[4-(氨基甲基)苯基]哌嗪-1-羧酸叔丁酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CA2672960A1 (en) * 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2009140101A2 (en) * 2008-05-12 2009-11-19 Boehringer Ingelheim International Gmbh Imidazopyridine compounds useful as mmp-13 inhibitors
IN2012DN04917A (enExample) * 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
RU2576662C2 (ru) * 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
WO2012143796A2 (en) * 2011-04-21 2012-10-26 Institut Pasteur Korea Anti-inflammation compounds
CN103324035B (zh) * 2013-06-20 2015-07-01 深圳市华星光电技术有限公司 掩膜板和阵列基板的制作方法

Also Published As

Publication number Publication date
RU2016107378A (ru) 2017-09-07
JP2016525562A (ja) 2016-08-25
WO2015014993A3 (en) 2015-04-02
JP2018158941A (ja) 2018-10-11
SG11201600686QA (en) 2016-02-26
EP3027615A2 (en) 2016-06-08
HUE056198T2 (hu) 2022-02-28
PH12016500207A1 (en) 2016-04-25
KR20170082450A (ko) 2017-07-14
EP3027615B1 (en) 2021-07-21
ES2883565T3 (es) 2021-12-09
JP2019131606A (ja) 2019-08-08
CN109575018A (zh) 2019-04-05
JP6757768B2 (ja) 2020-09-23
CN105745208A (zh) 2016-07-06
KR102292293B1 (ko) 2021-08-23
WO2015014993A2 (en) 2015-02-05
DK3027615T3 (da) 2021-10-25
US20160185774A1 (en) 2016-06-30
RU2734760C2 (ru) 2020-10-23

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014018502A2 (enExample)
BR112014019326A2 (enExample)
BR112014018516A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014017855A2 (enExample)
BR112014020341A2 (enExample)
BR112014018468A2 (enExample)
BR112016005365A2 (enExample)
BR112016015033A2 (enExample)
BR112016013278A2 (enExample)
BR112016003520A2 (enExample)
BR112015019515A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)
BR112016012407A2 (enExample)
BR112014017601A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)
BR112014018496A2 (enExample)